Heterogeneity of colon cancer: from bench to bedside
- PMID: 29209524
- PMCID: PMC5703395
- DOI: 10.1136/esmoopen-2017-000218
Heterogeneity of colon cancer: from bench to bedside
Abstract
The large bowel shows biomolecular, anatomical and bacterial changes that proceed from the proximal to the distal tract. These changes account for the different behaviour of colon cancers arising from the diverse sides of the colon-rectum as well as for the sensitivity to the therapy, including immunotherapy. The gut microbiota plays an important role in the modulation of the immune response and differs between the right colon cancer and the left colorectal cancer. The qualitative and quantitative difference of the commensal bacteria between the right side and the left side induces epigenetic changes in the intestinal epithelial cells as well as in the resident immune population. The second player in the pathological homeostasis of colorectal cancer is the differences of the genetic features of cancer cells and the different effects that microsatellite instability, chromosomal instability and the CpG island methylator phenotype induce on the immunological organisation of the tumour microenvironment. The third player is the immunological composition of the tumour microenvironment, which changes under the influence of both genetic structures and gut microbiota. All these three players influence each other. This review describes these three aspects, highlights their interactions and discusses data from reported clinical trials.
Keywords: Colon cancer; treatment response; tumor microenvironment.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway.Arch Pathol Lab Med. 2016 May;140(5):406-12. doi: 10.5858/arpa.2015-0310-RA. Arch Pathol Lab Med. 2016. PMID: 27128298 Review.
-
Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.Dis Colon Rectum. 2012 Feb;55(2):181-90. doi: 10.1097/DCR.0b013e31823c46ce. Dis Colon Rectum. 2012. PMID: 22228162
-
Differences Regarding the Molecular Features and Gut Microbiota Between Right and Left Colon Cancer.Ann Coloproctol. 2018 Dec;34(6):280-285. doi: 10.3393/ac.2018.12.17. Epub 2018 Dec 31. Ann Coloproctol. 2018. PMID: 30630301 Free PMC article.
-
Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.Tumour Biol. 2020 Jul;42(7):1010428320938492. doi: 10.1177/1010428320938492. Tumour Biol. 2020. PMID: 32635826
-
Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.Dan Med J. 2015 Jan;62(1):B4973. Dan Med J. 2015. PMID: 25557335 Review.
Cited by
-
Laterality: Immunological Differences Between Right-Sided and Left-Sided Colon Cancer.Ann Coloproctol. 2019 Dec;35(6):291-293. doi: 10.3393/ac.2019.11.11. Epub 2019 Dec 31. Ann Coloproctol. 2019. PMID: 31937068 Free PMC article. No abstract available.
-
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer.Front Immunol. 2019 Aug 20;10:1875. doi: 10.3389/fimmu.2019.01875. eCollection 2019. Front Immunol. 2019. PMID: 31481956 Free PMC article.
-
Precision Medicine for the Management of Therapy Refractory Colorectal Cancer.J Pers Med. 2020 Dec 11;10(4):272. doi: 10.3390/jpm10040272. J Pers Med. 2020. PMID: 33322358 Free PMC article.
-
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors.Cancers (Basel). 2022 Apr 12;14(8):1936. doi: 10.3390/cancers14081936. Cancers (Basel). 2022. PMID: 35454843 Free PMC article.
-
Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice.PeerJ. 2020 Dec 8;8:e9761. doi: 10.7717/peerj.9761. eCollection 2020. PeerJ. 2020. PMID: 33354412 Free PMC article.
References
-
- Nagasaki T, Hara M, Nakanishi H, et al. . Interleukin-6 released by Colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 2014;110:469–78. 10.1038/bjc.2013.748 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources